A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease.
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs PF 6669571 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Jul 2016 Status changed from recruiting to completed.
- 03 May 2016 Planned End Date changed from 1 Jul 2016 to 1 May 2016.
- 03 May 2016 Planned primary completion date changed from 1 Jul 2016 to 1 May 2016.